Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$14.68 USD

14.68
16,694,052

+2.36 (19.16%)

Updated Oct 2, 2024 03:57 PM ET

After-Market: $14.63 -0.05 (-0.34%) 5:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sweta Killa headshot

Best-Performing ETFs of Last Week

While the rally was broad-based, airline and banking industry led the way higher last week.

Tirthankar Chakraborty headshot

5 Top Stocks Up 100%+ in May With More Room to Run

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Sweta Jaiswal, FRM headshot

Here's Why You Should Invest in Momentum ETFs Now

Here we discuss whether the market conditions are more conducive to investing in momentum ETFs.

Sanghamitra Saha headshot

5 Reasons to Bet on Growth ETFs

A few upbeat developments on the vaccine front, unprecedented economic help, reopening of economies and a few bullish economic datapoints should facilitate growth stocks ahead.

    Sanghamitra Saha headshot

    5 High Beta ETFs That Are in High Momentum

    Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta ETFs that are in high momentum should gain ahead.

      Sweta Jaiswal, FRM headshot

      Biotech ETFs Soaring on COVID-19 Vaccine Progress

      Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.

      The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology

      The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology

      Sweta Killa headshot

      S&P Reclaims 3,000 Mark: Go Long With These ETFs

      Wall Street is rallying this quarter with the S&P 500 reclaiming its 3,000 level.

      Stock Market News for May 27, 2020

      The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.

      Sweta Killa headshot

      Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain

      The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.

      Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More

      The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

      Sweta Killa headshot

      Biotech ETF (BBC) Hits a New 52-Week High

      This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

      Uptick in Consumer Confidence Puts 3 Stocks on Top

      Consumer Confidence rose for the first time since February, reflecting Americans' optimism as the economy reopens.

      Nalak Das headshot

      Dow Touches 25,000 in More Than 2 Months: 4 Blue-Chip Picks

      The blue-chip index's northbound journey began on Mar 24 and is continuing barring occasional fluctuations.

      Sanghamitra Saha headshot

      Here's How Americans Are Regaining Confidence: 5 Picks

      U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.

        Mark Vickery headshot

        Pre-Markets Race Higher on Vaccine Hopes

        Chief among positives for the market is a new vaccine candidate for COVID-19 from Novavax (NVAX), which is launching its human trials in Australia.

        Economic Data Deluge

        Economic Data Deluge

        Kinjel Shah headshot

        Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial

        As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.

        Zacks.com headshot

        Novavax Begins Clinical Study for Coronavirus Vaccine

        Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.

        Tirthankar Chakraborty headshot

        2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks

        As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.

        Sanghamitra Saha headshot

        Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

        Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

        Ritujay Ghosh headshot

        Coronavirus Vaccine Development Gathers Steam: 4 Winners

        Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

        Jeremy Mullin headshot

        S&P Set to Open Above 3000

        Bulls start the week trying to break the 200-day moving average.

        Sweta Jaiswal, FRM headshot

        Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

        Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

        Sanghamitra Saha headshot

        Wining ETF Areas of Last Week

        Though last week was not upbeat for Wall Street, these ETFs breezed past Wall Street.